Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules

被引:1
作者
Wang, Wei [1 ,2 ]
Dong, Dong [1 ,2 ]
Chen, Liang [1 ]
Wang, Heng [1 ,2 ]
Bi, Bo [3 ]
Liu, Tianyi [1 ]
机构
[1] Fudan Univ, Huadong Hosp, Dept Plast & Aesthet Surg, Shanghai, Peoples R China
[2] Shanghai Med Coll Fudan Univ, Shanghai, Peoples R China
[3] Shanghai Changning Matern & Infant Hlth Hosp, Dept Cosmet Surg, Shanghai, Peoples R China
关键词
melanoma; TCGA; signature; immunotherapy; tumor microenvironment; DNA-DAMAGE RESPONSE; CHECKPOINT BLOCKADE; CANCER; TUMOR; EXPRESSION; IMMUNOPHENOTYPE; MECHANISMS; BIOMARKERS; LANDSCAPE; HALLMARKS;
D O I
10.3389/fgene.2022.893380
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Biomarker development for clinical checkpoint inhibition is still in its early stages. It is critical to determine the cause of the lack of a long-term response in patients after immune checkpoint blockade (ICB) treatment and to develop composite biomarkers or signatures to improve personalized approaches. Three modules that were significantly correlated with the immunotherapeutic response were identified. Stimulatory pathways of cellular immunity, extracellular matrix formation-related pathways, and ATP metabolism-related pathways were enriched. Two distinct transcriptional subtypes were determined. Tumor microenvironment (TME) characteristics were highly correlated with "hot" and "cold" tumors. The ICB score was significantly correlated with clinical characteristics including age, Breslow depth, Clerk level, AJCC stage, and T stage. Meanwhile, a low ICB score is characterized by increased activation of immunity, a higher level of immune infiltration, and immune molecule expression. The ICB score showed a robust ability to predict melanoma prognosis in the discovery, internal validation, and external validation cohorts. In addition, a low ICB score was linked to a higher CR/PR rate in the immunotherapeutic cohort. The ICB score could reflect the pre-existing immune features and the expression pattern of "Cold" versus "Hot" tumors in melanoma patients. Thus, it has the potential to serve as a reliable predictor of melanoma prognosis and response to ICB therapy.
引用
收藏
页数:19
相关论文
共 69 条
  • [1] Genomic Classification of Cutaneous Melanoma
    Akbani, Rehan
    Akdemir, Kadir C.
    Aksoy, B. Arman
    Albert, Monique
    Ally, Adrian
    Amin, Samirkumar B.
    Arachchi, Harindra
    Arora, Arshi
    Auman, J. Todd
    Ayala, Brenda
    Baboud, Julien
    Balasundaram, Miruna
    Balu, Saianand
    Barnabas, Nandita
    Bartlett, John
    Bartlett, Pam
    Bastian, Boris C.
    Baylin, Stephen B.
    Behera, Madhusmita
    Belyaev, Dmitry
    Benz, Christopher
    Bernard, Brady
    Beroukhim, Rameen
    Bir, Natalie
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Boland, Genevieve M.
    Bono, Riccardo
    Bootwalla, Moiz S.
    Bosenberg, Marcus
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brockway-Lunardi, Laura
    Brooks, Denise
    Brzezinski, Jakub
    Bshara, Wiam
    Buda, Elizabeth
    Burns, William R.
    Butterfield, Yaron S. N.
    Button, Michael
    Calderone, Tiffany
    Cappellini, Giancarlo Antonini
    Carter, Candace
    Carter, Scott L.
    Cherney, Lynn
    Cherniack, Andrew D.
    Chevalier, Aaron
    Chin, Lynda
    [J]. CELL, 2015, 161 (07) : 1681 - 1696
  • [2] xCell: digitally portraying the tissue cellular heterogeneity landscape
    Aran, Dvir
    Hu, Zicheng
    Butte, Atul J.
    [J]. GENOME BIOLOGY, 2017, 18
  • [3] Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
    Arora, Sanjeevani
    Velichinskii, Rodion
    Lesh, Randy W.
    Ali, Usman
    Kubiak, Michal
    Bansal, Pranshu
    Borghaei, Hossein
    Edelman, Martin J.
    Boumber, Yanis
    [J]. ADVANCES IN THERAPY, 2019, 36 (10) : 2638 - 2678
  • [4] Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
    Badalamenti, Giuseppe
    Fanale, Daniele
    Incorvaia, Lorena
    Barraco, Nadia
    Listi, Angela
    Maragliano, Rossella
    Vincenzi, Bruno
    Calo, Valentina
    Iovanna, Juan Lucio
    Bazan, Viviana
    Russo, Antonio
    [J]. CELLULAR IMMUNOLOGY, 2019, 343
  • [5] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
  • [6] Molecular determinants of response to PD-L1 blockade across tumor types
    Banchereau, Romain
    Leng, Ning
    Zill, Oliver
    Sokol, Ethan
    Liu, Gengbo
    Pavlick, Dean
    Maund, Sophia
    Liu, Li-Fen
    Kadel, Edward, III
    Baldwin, Nicole
    Jhunjhunwala, Suchit
    Nickles, Dorothee
    Assaf, Zoe June
    Bower, Daniel
    Patil, Namrata
    McCleland, Mark
    Shames, David
    Molinero, Luciana
    Huseni, Mahrukh
    Sanjabi, Shomyseh
    Cummings, Craig
    Mellman, Ira
    Mariathasan, Sanjeev
    Hegde, Priti
    Powles, Thomas
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [7] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    Barbie, David A.
    Tamayo, Pablo
    Boehm, Jesse S.
    Kim, So Young
    Moody, Susan E.
    Dunn, Ian F.
    Schinzel, Anna C.
    Sandy, Peter
    Meylan, Etienne
    Scholl, Claudia
    Froehling, Stefan
    Chan, Edmond M.
    Sos, Martin L.
    Michel, Kathrin
    Mermel, Craig
    Silver, Serena J.
    Weir, Barbara A.
    Reiling, Jan H.
    Sheng, Qing
    Gupta, Piyush B.
    Wadlow, Raymond C.
    Le, Hanh
    Hoersch, Sebastian
    Wittner, Ben S.
    Ramaswamy, Sridhar
    Livingston, David M.
    Sabatini, David M.
    Meyerson, Matthew
    Thomas, Roman K.
    Lander, Eric S.
    Mesirov, Jill P.
    Root, David E.
    Gilliland, D. Gary
    Jacks, Tyler
    Hahn, William C.
    [J]. NATURE, 2009, 462 (7269) : 108 - U122
  • [8] Immune checkpoint inhibitors to treat cutaneous malignancies
    Barrios, Dulce M.
    Do, Mytrang H.
    Phillips, Gregory S.
    Postow, Michael A.
    Akaike, Tomoko
    Nghiem, Paul
    Lacouture, Mario E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1239 - 1253
  • [9] Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
    Becht, Etienne
    Giraldo, Nicolas A.
    Lacroix, Laetitia
    Buttard, Benedicte
    Elarouci, Nabila
    Petitprez, Florent
    Selves, Janick
    Laurent-Puig, Pierre
    Sautes-Fridman, Catherine
    Fridman, Wolf H.
    de Reynies, Aurelien
    [J]. GENOME BIOLOGY, 2016, 17
  • [10] Understanding the tumor immune microenvironment (TIME) for effective therapy
    Binnewies, Mikhail
    Roberts, Edward W.
    Kersten, Kelly
    Chan, Vincent
    Fearon, Douglas F.
    Merad, Miriam
    Coussens, Lisa M.
    Gabrilovich, Dmitry I.
    Ostrand-Rosenberg, Suzanne
    Hedrick, Catherine C.
    Vonderheide, Robert H.
    Pittet, Mikael J.
    Jain, Rakesh K.
    Zou, Weiping
    Howcroft, T. Kevin
    Woodhouse, Elisa C.
    Weinberg, Robert A.
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 541 - 550